Surfactant protein A (SP-A) plays a role in host defense and inflammation in the lung. In the present study we investigated the hypothesis that SP-A is involved in bleomycin-induced pulmonary fibrosis. We studied the effects of human SP-A on bleomycin-induced cytokine production and mRNA expression in THP-1 macrophage-like cells and obtained the following results. 1) Bleomycin-treated THP-1 cells increased TNF-α, IL-8, and IL-1β production in dose and time-dependent patterns as we have observed with SP-A. TNF-α levels were unaffected by treatment with cytosine arabinoside. 2) The combined bleomycin/SP-A effect on cytokine production is additive by ribonuclease protection assay and synergistic by ELISA. 3) Although the bleomycin effect on cytokine production was not significantly affected by the presence of surfactant lipid, the additive and synergistic effect of SP-A/bleomycin on cytokine production was significantly reduced. We speculate that the elevated cytokine levels resulting from the bleomycin/SP-A synergism are responsible for bleomycin-induced pulmonary fibrosis and that surfactant lipids can help ameliorate pulmonary complications observed during bleomycin chemotherapy.
Introduction
Bleomycin is a group of glycopeptides isolated from Streptomyces verticillus. Although it is an effective antineoplastic agent, bleomycin-induced pulmonary fibrosis sometimes becomes fatal and limits the usefulness of the drug (34; 39) . The histological features of pulmonary fibrosis in human and animal studies include inflammatory cell recruitment, fibroblast proliferation and collagen synthesis (5) . A number of studies concerning the pathogenesis of pulmonary fibrosis have focused on the role of inflammatory cells, especially alveolar macrophage, in the fibrotic process. Bleomycin induces inflammatory cells from human and animal lung to secrete multifunctional cytokines, such as TNF-α, IL-1β, IL-8, and TGF-β (8; 9;
13; 33; 48). In a clinical study, TNF-α has been shown to be significantly increased after bleomycin infusion (35) .
The mechanism of bleomycin-induced cytokine production is not well understood. The cytotoxic effect of bleomycin is believed to be related to DNA damage that is characterized by the appearance of DNA damage-inducible proteins (25) and apoptosis (29) . There is also increased activity of NF-kB, which may result from the increase of reactive oxygen species by bleomycin (26) . NF-kB is a transcriptional factor that regulates the expression of many cytokine genes (50) . Among these, TGF-β is considered to be an important cytokine related to fibroblast proliferation and collagen synthesis (13; 48) and TNF-α is considered to be a central mediator in bleomycin-induced pulmonary fibrosis (27; 28; 49) . TNF-α receptor knockout mice have been shown to be protected from lung injury after exposure to bleomycin (27; 28) . 4 Pulmonary surfactant is essential for normal lung function. Surfactant protein A (SP-A), in addition to surfactant-related function (10) , plays a role in local host defense and regulation of inflammatory processes (3; 6) . SP-A is a collagenous C-type lectin or collectin (24) and its carbohydrate recognition domain (CRD) is involved in binding SP-A to pathogens and promoting phagocytosis of these pathogens by the macrophages (42; 43) . In the macrophagelike THP-1 cell line, human SP-A stimulates production of TNF-α, IL-1β, IL-8, and IL-6 in a dose-and a time-dependent manner (19; 36; 45) . Similar effects are seen in other cells of monocytic origin from both rats and humans (17; 19) . SP-A-enhanced TNF-α production appears to involve NF-κB activation (14) . SP-A also enhances immune cell proliferation (18) and increases expression of some cell surface proteins (16) . In addition, SP-A knockout mice show an increased susceptibility to infection (21) . A recent in vivo study suggests a role for SP-A in neutrophil recruitment into the lungs of preterm lambs (15) . There have also been reports with other systems in which an anti-inflammatory role has been attributed to SP-A (4).
Surfactant lipids (surfactant TA) can modulate adherence and superoxide production of neutrophils (37) . Surfactant lipids inhibit several SP-A regulated immune cell functions, including stimulation of macrophages (41) . Surfactant lipids and SP-A may be counterregulatory and changes in the relative amounts of surfactant lipids to SP-A may be important in determining the immune status of the lung. Although most of SP-A in the normal alveolar space is thought to be lipid-associated, "lipid-free" SP-A could increase if the balance between SP-A and surfactant lipid was altered under certain conditions (31) . There is evidence that bleomycin-induced lung injury in animal models is accompanied by qualitative and quantitative changes of surfactant 5 lipids (30; 38). Increased SP-A content in rat has been reported after intratracheal treatment of bleomycin (32; 44).
We hypothesized that "lipid-free" SP-A, the result of an imbalance of SP-A and surfactant lipids following bleomycin treatment, enhances the effects of bleomycin on proinflammatory cytokine production and may be partly responsible for bleomycin-induced pulmonary fibrosis.
In the present study, we examined the effects of SP-A on bleomycin-induced cytokine production and mRNA expression in THP-1 cells.
Materials and Methods

Cell culture
The THP-1 cell line was obtained from the American Type Culture Collection (Manassas, 
Stimulation of THP-1 cells with SP-A and bleomycin
After differentiation with 10 -8 M vitamin D 3 for 72h, THP-1 cells were pelleted and washed as described above. Cells at a density of 2 × 10 6 cells/ml were incubated in 24 well culture 7 plates. For dose-response study, cells were stimulated with bleomycin at concentrations ranging from 0-100 mU/ml. Time-dependent secretion of cytokines following bleomycin treatment was studied from 0-24h with 5 and 50 mU/ml of bleomycin. In experiments where the combined effects of SP-A and bleomycin were examined, SP-A (10 µg/ml) and bleomycin (5 or 50 mU/ml)
were added to cells simultaneously, unless otherwise noted. After treatment, the culture medium was collected at 4h or 6h for the ELISA assay of cytokine production and cells were harvested at 2h or 4h for cytokine mRNA analysis.
Cytosine arabinoside (Ara-C, Cytosar-U, Pharmacia & Upjohn, Kalamazoo, MI) was included in some experiments to confirm the specificity of the effect of bleomycin on proinflammatory cytokine production by THP-1 cells. Ara-C is another antineoplastic agent with known cytotoxicity (39) . Although it has not been associated with pulmonary fibrosis and cytokine production, it has been shown to cause non-cardiogenic pulmonary edema (11) . Ara-C, at concentrations ranging from 0.1 to 5 mM in culture medium, was used for evaluating the effect of Ara-C on TNF-α. The conditions employed in the Ara-C experiments were the same as those in bleomycin studies except that only a 4h time point was done.
Infasurf Inhibition of cytokine production
Infasurf (Forest Pharmaceuticals, St. Louis, MO), an extract of natural surfactant from calf lung, was used as a source of surfactant lipid. Infasurf was supplied by the manufacturer as a suspension containing 35mg phospholipids/ml of sterile saline. Infasurf is predominately phosphatidylcholine and contains ∼2% wt/wt protein that includes SP-B and SP-C, but no SP-A.
Infasurf in concentrations ranging from 100 to 800 µg/ml was used in the experiments for ELISA 8 assay of cytokine production, but only a single dose (400 µg/ml) of Infasurf was used in the experiment for mRNA analysis. Infasurf was preincubated separately with SP-A (10 µg/ml), bleomycin (5 mU/ml), and SP-A + bleomycin for 15min at 37 o C before addition to the THP-1 cells. Cells were incubated for 4h after the treatment. Culture medium and cell pellets were then collected for ELISA assay and mRNA analysis, respectively.
ELISA assay
The ELISA assays for TNF-α, IL-8, and IL-1β (OptEIA Human ELISA Sets, Pharmingen, San Diego, CA) were performed according to the instructions recommended by the manufacturer. The ELISA kits were capable of measuring levels of 7.8-500 pg/ml for TNF-α, 6.2-400 pg/ml for IL-8 and 20-1000 pg/ml for IL-1β. A reference curve for each of these cytokines was obtained by plotting the concentration of several dilutions of standard protein versus the corresponding absorbance.
Analysis of cytokine mRNA
Total RNA was isolated from THP-1 cells at 2h or 4h after treatment by using RNeasy Mini Kits (QIAGEN, Valencia, CA) according to the protocol of the RNeasy Mini Handbook.
Cytokine mRNA quantification was performed by ribonuclease protection assay (RPA). housekeeping genes were also included to allow for normalization of sampling or technical error.
Aliquots of 2µg of total RNA were hybridized with radiolabeled probes at 56 o C for 16h. RNase treatment followed, resulting in degradation of single-stranded RNA and free probes. After inactivation and precipitation, protected probes were resolved by a 5% polyacrylamide-urea sequence gel electrophoresis and visualized by autoradiography. Densities of the protected bands were quantified by soft laser densitometry. The mRNA level is expressed as the ratio of the densitometric value of each cytokine mRNA to that of the L32 or GAPDH mRNA.
Statistics
Values are presented as means ± SEM. Data were analyzed using SigmaStat statistical software. For each experiment, statistical treatment included a one way analysis of variance (ANOVA) followed by a Student-Newman-Keuls test for pairwise comparison and was judged to be significantly different at p<0.05.
Results
Dose-response and time course studies of bleomycin effects on stimulation of cytokine production by THP-1 cells.
To study the response of THP-1 cells to bleomycin stimulation, we first performed a doseresponse and a time course of bleomycin effects on TNF-α, IL-8, and IL-1β levels. The concentrations of bleomycin for the dose-response study ranged from 0-100 mU/ml, which spans a relevant pharmacological dose (33) . As shown in Figure 1 , a bleomycin concentration as low as 0.5 mU/ml increased both TNF-α and IL-8 levels (panels A and B), but a higher concentration of bleomycin (50 mU/ml) was needed to increase the IL-1β level significantly (panel C).
Cytokine production continued to increase as the bleomycin dose was increased to 100 mU/ml.
In contrast, the TNF-α level after Ara-C treatment did not differ from that of control (panel D). (starting point) was low. The increase of TNF-α levels was usually detected at 3h following bleomycin treatment and quickly reached a maximum by 4 to 6h depending on the dose selected ( Fig. 2A) . The content of TNF-α subsequently decreased and returned to background levels at 24h. Initially, IL-8 had a similar response pattern to TNF-α, with respect to its increase and peak response time, but after reaching maximal level at around 5h, IL-8 didn't show a significant decline until 24h (Fig. 2B) . The level of IL-1β increased much later (Fig. 2C) than that of TNF-α and IL-8, and reached a peak at 10h after bleomycin treatment. Unlike that of TNF-α and IL-8, the level of IL-1β then did not decline, but remained elevated over the 24h test period.
The combined effect of SP-A and bleomycin on cytokine production and mRNA expression by THP-1 cells.
After testing the effects of bleomycin treatment on TNF-α, IL-1β and IL-8 production by
THP-1 cells, we examined the combined effects of SP-A and bleomycin on cytokine production.
A dose of 10 µg/ml of SP-A was chosen rather than the dose of 50 µg/ml we have used in previous experiments (19; 45) , as the low dose may better identify synergistic or additive effects of the two substances. As shown in Figure 3A , TNF-α values induced by SP-A (10 µg/ml) alone and bleomycin (5 mU/ml) alone were 86.6 ± 11.5 pg/ml and 45.9 ± 10.6 pg./ml, respectively.
But the combined treatment increased the level to 201.7 ± 34.3 pg/ml. High concentration of bleomycin (50 mU/ml) alone induced a TNF-α level of 82.1 ± 17.3 pg/ml, while the value of the combined effect was 416 ± 61.9 pg/ml. There was a similar response pattern for IL-8 when the combined effects of SP-A and bleomycin were examined (Fig. 3B) . Because IL-1β reached a maximum value at a later time point than TNF-α and IL-8 did, we measured its level at 6h after treatment. The means of IL-1β levels (Fig.3C) induced by the combined treatment were greater than the sum of the separate means by SP-A or bleomycin alone as we saw with TNF-α and IL- When SP-A (10 µg/ml) was preincubated with bleomycin (50mU/ml) 15min before addition to the cells, the TNF-α level was significantly lower than that without preincubation (Fig.5) .
However, the synergistic effects on TNF-α production remained. There was a similar response with respect to IL-8 production (Data not shown).
The inhibitory effect of Infasurf on SP-A and bleomycin-induced cytokine production and mRNA expression.
We examined the ability of surfactant lipids to modulate cytokine level. As shown in Fig. 6 , Infasurf had no effect on TNF-α level in the absence of SP-A and bleomycin. SP-A-induced TNF-α level was significantly reduced by Infasurf at 100 µg/ml and was totally inhibited with a higher dose of Infasurf. In contrast, the bleomycin effect was not significantly reduced by Infasurf even at 800µg/ml. Infasurf decreased the TNF-α level induced by SP-A + bleomycin in a dose-dependent pattern. The TNF-α level was significantly decreased from 226.8 ± 35.7 pg/ml in the absence of Infasurf to 109 ± 19.3 pg/ml and 41.5 ± 0.7 pg/ml at 200 µg/ml and 800 µg/ml of Infasurf, respectively.
Similar results were obtained when we measured TNF-α and IL-8 mRNA expression by RPA (Fig.7) . TNF-α mRNA expression induced by SP-A was totally inhibited by Infasurf (400 µg/ml), but at the same time bleomycin-induced TNF-α mRNA level was not significantly changed. In SP-A + bleomycin treatment, the relative intensity of TNF-α mRNA was decreased from 3.17 ± 0.71 in the absence of Infasurf to 1.14 ± 0.10 in the presence of Infasurf. A similar response pattern was also seen for IL-8 mRNA after Infasurf treatment.
Discussion
In the present study, we investigated whether SP-A plays a role in bleomycin-induced processes. These models include neonatal hyperoxia (7), sepsis (23) , and preterm ventilated sheep (15) . On the other hand, in the SP-A knockout mouse (21) and in a very premature baboon (2) the lack of SP-A appears to cause increased inflammation. In both of these models there is a significant delay in pathogen clearance, which is likely to prolong the proinflammatory stimulus provided by the pathogen. However, in the presence of SP-A, pathogen clearance is enhanced and this may result in reduced inflammation due to removal of the proinflammatory stimulus provided by the pathogen.
While SP-A clearly enhances many aspects of host-defense function, these different lines of evidence prevent it from being easily classified as pro-inflammatory or anti-inflammatory. It is possible that its role changes at different stages of the inflammatory response, as has been
proposed recently for NF-kB (20) .
In the present study, we showed that SP-A in low dose (10 µg/ml) significantly increased cytokines at both the protein and mRNA levels. LPS (0.1 ng/ml) was used as a positive control in the present study. A striking difference in IL-1β mRNA expression between LPS and SP-A treated cells was observed, especially at 2h after treatment (Fig. 4A) . The relative intensity of IL-1β mRNA induced by LPS was 18-fold greater than that induced by SP-A (0.92 ± 0.23 vs 0.05 ± 0.02), while the differences between LPS and SP-A in TNF-α or IL-8 mRNA are only around 2-fold. These data may provide additional evidence that the regulation of proinflammatory cytokine production by SP-A in THP-1 cells occurs by a different pathway than that utilized by LPS (36) .
Under normal physiological conditions, most of the SP-A in the alveoli is combined with surfactant lipids in the form of a surfactant lipoprotein complex. Our data suggest that these SP-A/lipid complexes do not affect cytokine production, perhaps because the complexed SP-A is unable to interact directly with immune cells (36) . Therefore, it is possible that if the lipids are reduced in quantity or quality, the stimulatory influence of SP-A could be enhanced. In fact, in bleomycin-induced pulmonary fibrosis, changes in surfactant composition and function have been revealed in animal models (30; 38) . Studies in rat indicate that there is significant increase of SP-A but not of surfactant phospholipids in response to bleomycin treatment (32; 44). We showed that although surfactant lipids by themselves had no effect on cytokine production, The mechanism of bleomycin-induced cytokine production has not been fully elucidated. It is generally believed to be related to DNA damage (25) , apoptosis (29) and activation of NF-kB (50) . It has also been demonstrated that bleomycin-induced injury is associated with the generation of reactive oxygen species, particularly superoxide anion (26; 37) . We speculate that this mechanism involves the production of reactive oxidants by the bleomycin-treated cells, which in turn activate NF-kB and increase transcription of cytokine genes. Although the mechanism of action of SP-A is not known either, it is likely that it involves interaction with a cell membrane molecule, possibly the C1q receptor (22), activating intracellular events including the eventual activation of NF-kB (14) . When SP-A and bleomycin were added to the cell at the same time, the levels of both TNF-α and IL-8 were higher than the sum of each cytokine induced In summary, we have demonstrated that both SP-A and bleomycin can stimulate production of inflammatory cytokines by THP-1 cells and that there is a synergistic effect when both agents are used. Surfactant lipids significantly suppress the synergistic SP-A/bleomycin effect on cytokine production. We speculate that the significantly elevated cytokine levels resulting from this synergism are responsible for bleomycin-induced pulmonary fibrosis and that surfactant lipids can help ameliorate pulmonary complication observed during chemotherapy. 
